Emisphere Technologies acquisition completes for $1.35 billion

Novo Nordisk completed its acquisition of Emisphere Technologies for $1.35 billion on December 8, 2020, bringing in-house the drug-delivery technology known as SNAC — the absorption enhancer that allows semaglutide, a peptide, to be swallowed as a tablet rather than injected. The deal also ended Novo Nordisk's obligation to pay outside royalties on that technology.

Semaglutide is the active molecule in Ozempic and Wegovy, both injections, and in Rybelsus, the tablet form. Peptides like semaglutide are normally broken down in the stomach and poorly absorbed, which is why most drugs in this class are given by injection. SNAC is co-formulated with semaglutide in the tablet to help enough of the drug cross into the bloodstream to work. The specific pharmacology of SNAC, the exact terms of the purchase agreement, and the royalty rates Novo Nordisk had been paying are not detailed in the source material provided here, so those numbers should be treated as not established in this report.

Who bought what

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, formed in 1989 through the merger of two Danish firms whose roots go back to the 1920s ^[1]. It is controlled by Novo Holdings A/S, which holds roughly 28.1% of its shares and 77.1% of its voting shares ^[1]. The company markets its products in 168 countries ^[1], and its portfolio includes Ozempic, Wegovy, Saxenda and Victoza alongside its insulin franchise ^[1]. Net sales in 2024 were about $42.1 billion ^[1]. (The Wikipedia entry used as a source here carries a maintenance notice warning it may have been edited in return for undisclosed payments, so its corporate detail should be read with that caveat ^[1].)

Against that backdrop, a $1.35 billion outlay was a relatively contained bet — but it locked up a piece of technology that no competitor can license for its own oral peptide programs.

Why it matters for patients

The practical link between a 2020 corporate deal and a 2026 pharmacy shelf is ownership of the formulation. Every oral semaglutide product Novo Nordisk sells depends on the SNAC carrier acquired in this transaction. That includes Rybelsus, the oral semaglutide tablet approved for type 2 diabetes, and the oral version of Wegovy for weight management that the company has targeted for 2026 under the development record for this story.

For people who dislike needles, cannot store a refrigerated pen, or travel in ways that make injections awkward, a tablet changes the day-to-day experience of treatment. Owning the technology outright also removes a royalty layer from Novo Nordisk's cost structure on those pills, though whether that translates into lower list prices, lower out-of-pocket costs, or simply higher margins is not addressed in the available sources and remains unknown.

There is a second consequence worth understanding: exclusivity. Because SNAC is now wholly owned rather than licensed, rival manufacturers cannot simply pick up the same carrier to build their own oral GLP-1 tablets. That pushes competitors toward different approaches — for example, small-molecule pills such as orforglipron (Foundayo), which do not need an absorption enhancer because they are not peptides. The size of that competitive gap, and how it affects supply or pricing for US patients, is not something the sources here quantify.

Oral and injectable forms of the same molecule are not interchangeable in dose or in how they are taken, and the comparative effectiveness data for oral versus injected semaglutide is outside the scope of the sources used for this article.

What happens next

• December 8, 2020: Acquisition of Emisphere Technologies completed for $1.35 billion, transferring SNAC to Novo Nordisk.
• 2026: An oral Wegovy (semaglutide) product is expected to reach the market, built on the same SNAC platform, per the development record for this story. Exact launch timing, pricing and coverage details are not yet known from the sources here.

Anyone weighing an oral versus injectable option should look to the prescribing information and their own clinician rather than to corporate deal history for guidance.